At a glance Selected evidence in this atlas Studied use & population Chinese adults with overweight or obesity without diabetes
Study context Selected efficacy evidence 13.32% reported weight loss · 2.45% loss with placebo · 22 weeks
HDM1005 phase 2 obesity trial · Phase 2 · sponsor · 4 mg once weekly · Regardless of stopping treatment
Evidence & limitations Important safety context No permanent AE discontinuations; no treatment-related serious events; nausea2.1–18.8% across doses.
Safety context Study results apply to their own population, dose and analysis. They do not establish a ranking between therapies.
At a glance Evidence & safety Development timeline Biology & identity Molecule
Evidence in the atlas 1 result Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.
Weight loss 13.32% reported weight loss · 2.45% loss with placebo · 22 weeks
4 mg once weekly
Chinese adults with overweight or obesity without diabetes
Treatment-policy analysis reported in ADA abstract. Phase 3 obesity enrollment completed; phase 2 head-to-head tirzepatide ongoing.
Safety context No permanent AE discontinuations; no treatment-related serious events; nausea2.1–18.8% across doses.
Limitations: Conference abstract; exact arm sample size not stated; phase 3 results not yet located.
Biology & identity Status in this atlas: Phase 3 obesity enrollment completed; phase 2 head-to-head tirzepatide ongoing. Status source
Hormone activity Activates both GLP-1 and GIP receptors.
What do these hormones do? GLP-1 · GIP
No approved trade name verified. Poterepatide is the generic name and HDM1005 is its development code.
Huadong Medicine / Hangzhou Zhongmei Huadong Pharmaceutical · Originator and clinical developer; trials sponsored through its pharmaceutical subsidiary.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule Activates both GLP-1 and GIP receptors.
Structure not yet verified Structure not verified Activates both GLP-1 and GIP receptors.
Shown: Peptide drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.
Poterepatide Development timeline Next milestone A next milestone is not summarized for this therapy. This does not mean development has ended.
Development history 3 selected milestones Poterepatide · compound history across indications
Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.
Apr 2025
Obesity phase 2 completes enrollment Huadong's half-year report records complete enrollment in the obesity phase 2 trial.
Source Oct 2025
Obesity phase 3 starts enrollment Huadong reported the first participant in the phase 3 weight-management trial in October 2025.
Source Jun 2026
Obesity phase 2 results at ADA The randomized 22-week trial reported treatment-policy weight reductions across four HDM1005 doses.
Source Selected sources checked Sep 13, 2026. This is not an exhaustive history.